All In Biotech

Drug Trial Radar · NCT05467033

Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin

Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 424 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

424

Planned (sponsor's estimate)

Start

Sep 1, 2022

Primary completion

Aug 31, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
Medical University of BialystokAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.

Conditions

  • Kidney Biopsy

Interventions

  • DesmopressinDrug

    desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;

  • intravenous infusion NaClDrug

    0,9% NaCl managed as intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bleeding events in 24 hours after the procedureTime frame: 24 hours after kidney biopsy
  2. Bleeding events in 48 hours after the procedureTime frame: 48 hours after kidney biopsy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • II Department of Nephrology and Hypertension

    Bialystok, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.